Compare TALK & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TALK | TBPH |
|---|---|---|
| Founded | 2012 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 442.1M | 993.7M |
| IPO Year | N/A | N/A |
| Metric | TALK | TBPH |
|---|---|---|
| Price | $3.92 | $18.24 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $4.83 | ★ $27.80 |
| AVG Volume (30 Days) | ★ 1.2M | 490.2K |
| Earning Date | 02-19-2026 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | 0.03 | ★ 0.58 |
| Revenue | ★ $214,593,000.00 | $80,327,000.00 |
| Revenue This Year | $23.86 | $70.78 |
| Revenue Next Year | $22.22 | N/A |
| P/E Ratio | $144.07 | ★ $31.74 |
| Revenue Growth | 18.37 | ★ 27.12 |
| 52 Week Low | $2.22 | $7.90 |
| 52 Week High | $4.36 | $20.33 |
| Indicator | TALK | TBPH |
|---|---|---|
| Relative Strength Index (RSI) | 68.50 | 50.55 |
| Support Level | $3.45 | $17.59 |
| Resistance Level | $3.71 | $19.22 |
| Average True Range (ATR) | 0.16 | 0.59 |
| MACD | 0.01 | -0.10 |
| Stochastic Oscillator | 99.01 | 50.38 |
Talkspace Inc is a behavioral healthcare company offering access to licensed therapists, psychologists, and psychiatrists through its technology platform. It serves clients including health plans, enterprises, and individual subscribers. Therapists address various mental health conditions, while psychiatrists cater to a higher acuity demographic. Revenue stems from payor and direct-to-enterprise clients, with contracts lasting one to three years. The majority of the Company's operations and revenues are based in the United States.
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).